Literature DB >> 1105629

The effect of lithium treatment on manic symptoms and levels of monoamine metabolites in cerebrospinal fluid of manic depressive patients.

B Fyrö, U Petterson, G Sedvall.   

Abstract

Clinical effects, levels of 5-hydroxyindoleacetic acid (5-HIAA) and homovanillic acid (HVA) in cerebrospinal fluid (CSF) and lithium levels in serum were examined in 13 manic depressive patients acutely admitted because of a manic or hypomanic episode. Patients were examined before and 12 days after the beginning of lithium treatment. Manic scores were significantly reduced during treatment. The levels of 5-HIAA as well as HVA increased significantly during treatment. The HVA to 5-HIAA ratio was significantly reduced, indicating a more pronounced change in 5-HIAA than in HVA. The 5-HIAA and HVA levels before as well as after 12 days of treatment were significantly correlated. No significant correlation was found between manic scores and monoamine metabolites in CSF or between lithium level in serum and reduction of manic scores or elevation of monoamine metabolites in CSF in the relative small number of patients studied.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1105629     DOI: 10.1007/bf00421192

Source DB:  PubMed          Journal:  Psychopharmacologia


  3 in total

Review 1.  Lithium and serotonin function: implications for the serotonin hypothesis of depression.

Authors:  L H Price; D S Charney; P L Delgado; G R Heninger
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

2.  Serotonergic function during lithium augmentation of refractory depression.

Authors:  E McCance-Katz; L H Price; D S Charney; G R Heninger
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Cerebrospinal fluid monoamine metabolite profiles in bipolar disorder, ADHD, and controls.

Authors:  Erik Pålsson; Carl Sellgren; Eleonore Rydén; Ruth Kizza; Aurimantas Pelanis; Henrik Zetterberg; Kaj Blennow; Mikael Landén
Journal:  J Neural Transm (Vienna)       Date:  2017-06-27       Impact factor: 3.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.